Showing results 2 to 2 of 2
< previous
Title | Author(s) | Issue Date | |
---|---|---|---|
Garadacimab for hereditary angioedema prophylaxis: Long-term efficacy and safety from the VANGUARD Phase 3b open-label extension trial (first interim analysis) Proceeding/Conference:13th C1-inhibitor Deficiency & Angioedema Workshop | 2023 |